Tian-Shung Wu

This inventor holds 16 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignees: China Medical University, The University of North Carolina at Chapel Hill, Medical and Pharmaceutical Industry Technology and Development Center. Active years: 1996-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tian-Shung Wu. Retrieved from https://idiyas.com/inventor/tian-shung-wu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 2)

% Patents Active = 75.0

CIPO Patents = 2

EPO Patents = 6 (Patent Applications = 3)

Average Co-Inventor Count = 5.6

ph-index = 2

Forward Citations = 30(Granted Patents)

Location History:

Tainan City, TW (1996)
Tianan, TW (2012)
Taichung, TW (2016)
Tainan, TW (1997 - 2017)

Company Filing History:

5 out of 110

China Medical University

patents

5 out of 1,327

The University of North Carolina at Chapel Hill

patents

2 out of 16

Medical and Pharmaceutical Industry Technology and Development Center

patents

4. 2 out of 544

National Science Council

patents

5. 1 out of 21

China Medical University Hospital

patents

6. 1 out of 2

National Science Council of Taiwan

where one patent can have more than one assignee

Years Active: 1996-2017

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9718835 - [object Object] (2017-08-01),

2. 9266813 - Stilbenoid compound as inhibitor for squamous carcinoma and hepatoma and uses thereof (2016-02-23),

3. 9029394 - 2-phenyl-4-quinolones as anticancer agents (2015-05-12),

4. 9023867 - Hydrophilic derivatives of 2-selenophene-4-quinolones as anticancer agents (2015-05-05),

5. 9023866 - 2-selenophene-4-quinolones as anticancer agents (2015-05-05),

6. 8524740 - Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives (2013-09-03),

7. 8440692 - Hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents (2013-05-14),

8. 8188089 - Tylophorine analogs as antitumor agents (2012-05-29),

9. 7795299 - Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents (2010-09-14),

10. 7531519 - Polygalatenosides and use thereof as an antidepressant agent (2009-05-12),

11. 7495026 - Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents (2009-02-24),

12. 6946153 - Anti-fungal pharmaceutical compositions comprising an active ingredient prepared from Zingiber officinale (2005-09-20),

13. 6274177 - Method of preparing an extract potent in anti-inflammation and anti-platelet aggregation from Zingiber officinale and pharmaceutical compositions containing said extract (2001-08-14),

14. 5853731 - Thromboxane A2 Receptor antagonism and antioxidant action of (1998-12-29),

15. 5656274 - Thromboxane A.sub.2 receptor antagonism and antioxidant action of (1997-08-12),

Title: **Innovations of Tian-Shung Wu: A Journey Through Antitumor Agent Development**

Introduction

Tian-Shung Wu, a prolific inventor based in Tainan, Taiwan, has made significant contributions to the field of medicinal chemistry, particularly in the development of antitumor agents. With a total of 16 patents to his name, his work has provided new avenues for treating various cancers, showcasing his commitment to innovative healthcare solutions.

Latest Patents

Wu's recent patents highlight his focus on creating novel therapeutic compounds. One of his latest inventions involves 20-sulfonylamidine derivatives of camptothecin, which are aimed at treating tumors related to nasopharyngeal, lung, breast, or prostate cancers. Another notable patent includes a series of stilbenoid derivatives that act as inhibitors for head and neck squamous cell carcinoma and hepatoma, demonstrating Wu's dedication to addressing critical health issues through research and innovation.

Career Highlights

Throughout his career, Wu has worked at prestigious institutions such as the University of North Carolina at Chapel Hill and China Medical University. His efforts in research and development have not only advanced his personal career but have contributed significantly to the scientific community's understanding of cancer therapies.

Collaborations

Wu's innovative work has often been in collaboration with notable colleagues, including Sheng-Chu Kuo and Kuo-Hsiung Lee. Through teamwork and collaboration, these inventors have been able to enhance their research and produce impactful innovations that resonate within the medical field.

Conclusion

Tian-Shung Wu's journey as an inventor illustrates the powerful intersection of science and innovation. His numerous patents reveal his relentless pursuit of solutions to pressing medical challenges, particularly in cancer treatment. As he continues to develop new compounds, the potential for improved therapies remains high, promising a brighter future for cancer patients.

Profile summary based on public USPTO records.